IOVANCE BIOTHERAPEUTICS, INC. Derivative Liability, Current
IOVANCE BIOTHERAPEUTICS, INC. (IOVA) had Derivative Liability, Current of $7.66 million as of 2012-09-30, per its 10-Q filed 2013-01-25.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:DerivativeLiabilitiesCurrent · last filed 2013-09-23
- 2012-09-30: Derivative Liability, Current $7.66M.
- 2012-06-30: Derivative Liability, Current $8.74M.
- 2012-03-31: Derivative Liability, Current $10.67M.
- 2011-12-31: Derivative Liability, Current $7.94M.
| Period end | Derivative Liability, Current |
|---|---|
| 2012-09-30 | $7.66M 10-Q · filed 2013-01-25 |
| 2012-06-30 | $8.74M 10-Q/A · filed 2012-09-10 |
| 2012-03-31 | $10.67M 10-Q · filed 2012-05-15 |
| 2011-12-31 | $7.94M 10-K · filed 2013-09-23 |
| 2011-09-30 | $6.29M 10-Q · filed 2011-11-21 |
| 2011-06-30 | $1.74M 10-Q/A · filed 2011-09-01 |
| 2010-12-31 | $792.58K 10-K · filed 2012-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |